Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has been given an average recommendation of “Buy” by the seven brokerages that are presently covering the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $9.05.

DRNA has been the subject of several research reports. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Monday, February 6th. HC Wainwright initiated coverage on shares of Dicerna Pharmaceuticals in a research report on Monday, December 12th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Leerink Swann reiterated a “buy” rating and set a $8.00 price objective on shares of Dicerna Pharmaceuticals in a research report on Tuesday, November 8th.

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 3.03 on Friday. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $6.50. The stock’s 50 day moving average is $2.80 and its 200-day moving average is $3.39. The company’s market cap is $62.88 million.

Institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Dicerna Pharmaceuticals by 7.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,978 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 2,705 shares during the period. Renaissance Technologies LLC raised its position in Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 84,682 shares during the period. Finally, RTW Investments LP raised its position in Dicerna Pharmaceuticals by 0.8% in the fourth quarter. RTW Investments LP now owns 2,043,216 shares of the biopharmaceutical company’s stock valued at $5,884,000 after buying an additional 16,322 shares during the period. Institutional investors and hedge funds own 58.56% of the company’s stock.

“Analysts Set Dicerna Pharmaceuticals, Inc. (DRNA) PT at $9.05” was reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The correct version of this piece of content can be accessed at http://www.dailypolitical.com/2017/02/17/analysts-set-dicerna-pharmaceuticals-inc-drna-pt-at-9-05.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.